PRINCETON JUNCTION, N.J., April 14, 2025 (GLOBE NEWSWIRE) -- MISTRAS Group, Inc. (NYSE:MG), the leading provider of integrated technology-enabled asset protection solutions, today announced the appointment of Cliff Schaffer as Senior Vice President of In-Lab Services. Reporting to Hani Hammad, Executive Vice President and Chief Operating Officer, Schaffer will lead MISTRAS' in-lab strategy and operations across North America, with a focus on scaling services for aerospace and defense and heavy manufacturing ...

Core Viewpoint - Theriva Biologics is presenting interim blinded safety and pharmacokinetic data for SYN-004 at the ESCMID Global Congress, focusing on its potential to prevent acute graft-versus-host disease in allogeneic hematopoietic cell transplant recipients [1][3]. Group 1: Clinical Trial Details - The ongoing Phase 1b/2a clinical trial is randomized, double-blinded, and placebo-controlled, evaluating the safety and tolerability of oral SYN-004 in allogeneic HCT recipients receiving IV antibiotics [3]. - The trial is being conducted at Washington University School of Medicine and aims to enroll up to 36 participants across three cohorts, each receiving different IV beta-lactam antibiotics [3]. - Safety and pharmacokinetic data are reviewed by an independent Data and Safety Monitoring Committee to determine the progression to the next cohort [3]. Group 2: About SYN-004 - SYN-004 (ribaxamase) is designed to degrade certain IV beta-lactam antibiotics in the gastrointestinal tract, maintaining gut microbiome balance and preventing Clostridioides difficile infection and acute graft-versus-host disease [4][6]. - A previous Phase 2b clinical trial with 412 patients showed that SYN-004 protected the gut microbiome from antibiotic-mediated dysbiosis, leading to better maintenance and recovery of the microbiome [4]. Group 3: Company Overview - Theriva Biologics is a diversified clinical-stage company focused on developing therapeutics for cancer and related diseases, with a subsidiary working on an oncolytic adenovirus platform [5][6]. - The company's lead candidates include VCN-01, SYN-004, and SYN-020, targeting various aspects of cancer treatment and microbiome protection [6].

Core Insights - MISTRAS Group, Inc. is celebrating its growing interest and adoption of asset protection solutions in various industries by ringing the opening bell at the New York Stock Exchange [1] - The company is well-positioned for expansion and growth in 2025 due to a data-driven approach and increasing demand for asset protection in energy, manufacturing, and aerospace and defense sectors [2][3] Company Overview - MISTRAS Group is a leading multinational provider of integrated technology-enabled asset protection solutions, focusing on maximizing safety and operational uptime for critical industrial and civil assets [6][7] - The company emphasizes a technology-first mindset, utilizing advanced testing, inspection, and real-time intelligence to meet customer needs for compliance, uptime, and cost reduction [3][4] Industry Positioning - MISTRAS operates in asset-intensive industries where minimizing downtime is crucial, as disruptions can lead to significant financial losses [4] - The company collaborates with major clients globally to address complex challenges in sectors such as oil and gas, aerospace, renewable and nonrenewable power, civil infrastructure, and manufacturing [7][8] Technological Capabilities - MISTRAS enhances value for clients by integrating asset protection throughout supply chains and utilizing Industrial IoT-connected digital software and monitoring solutions [8] - Core capabilities include non-destructive testing, advanced robotics, laboratory quality control, sensing technologies, and mechanical integrity engineering services [8]

BASF SE (BASFY) has enhanced its Sunscreen Simulator, a digital platform designed for the development and optimization of sun care formulations. The updated version will be officially unveiled at this year’s in-cosmetics Global event, taking place from April 8 to April 10 in Amsterdam.A key new technical feature is the ability to choose from various formulation types, such as oil in water (O/W), water in oil (W/O), or oils, to assess how the sunscreen formulation base affects performance. Taking into accoun ...

LONDON, April 3, 2025 /PRNewswire/ -- Today, Corero Network Security (AIM: CNS) (OTCQX: DDOSF), the distributed denial of service (DDoS) protection specialists, announced a new strategic partnership with Brazil-based TechEnabler to expand their existing Corero DDoS Protection-as-a-Service (DDPaaS) solution with the additional of the Corero 3400 400G appliances. This agreement marks the latest in a series of significant wins in Brazil, where Corero has secured four deals in the past four months totaling over ...

LONDON, April 1, 2025 /PRNewswire/ -- Corero Network Security (AIM: CNS) (OTCQX: DDOSF), the DDoS protection specialists, today announced an expansion of its partnership with Juniper Networks, enabling Juniper to sell Corero's full portfolio of DDoS protection solutions to customers, regardless of their existing network infrastructure. Corero Network Security is a leading provider of DDoS protection solutions, specializing in automatic detection and protection solutions with network visibility, analytics, a ...

Inspired by the legendary 'You Can't See Me' catchphrase, the Sunscreen You Can't See campaign reinforces that while you may not see Ultra Sheer ® Sunscreen on your skin, the high-SPF mineral formula is working hard to protect you from the harshest UV rays. Joining Cena in the campaign is dermatologist and skin cancer surgeon Dr. Neera Nathan. "I had a blast working on this campaign. It's funny, but it also gets across a really important point—wearing SPF every day isn't something you should skip," said Joh ...

Inspired by the legendary 'You Can't See Me' catchphrase, the Sunscreen You Can't See campaign reinforces that while you may not see Ultra Sheer ® Sunscreen on your skin, the high-SPF mineral formula is working hard to protect you from the harshest UV rays. Joining Cena in the campaign is dermatologist and skin cancer surgeon Dr. Neera Nathan. "I had a blast working on this campaign. It's funny, but it also gets across a really important point—wearing SPF every day isn't something you should skip," said Joh ...

三高 腰椎脊椎疾病 失眠 | 在高压的工作下,三高、腰椎脊椎疾病、 失眠也渐渐成为了年轻人的高发疾病,越 来越"脆皮"的年轻人,渐渐意识到保 险的重要性。 熬夜时的"隐秘投资" 晚上10点,你一般都在做什么?追剧? 还是在刷社交媒体?有些年轻人,他们 正忙着投保健康险! 某平台数据显示80后和90后更喜欢在 晚上22点之后买保险,不知道这些投保 者里有没有你呢? Hob a ume lar Z M � ● 0 ● . 0 ● ● ● ● ● � � 0 ● 0 ● ● 0 ● ● ● . ● ● � ● . ● . ● 0 � 0 ● ● 0 ● ● 0 . ● . o 上学时怕考试,工作后怕体检,体检报告 成为了当代职场人怕面对的"成绩单",一边拼 命,一边惜命,说的是不是你? 某平台80后和90后职场人健康险投保时间分布 5点 0点 10点 18点 22点 那么问题来了:不同阶段的职场人,究 竟该如何配置保险呢? 首先,了解自己的需求是 挑选保险的关键,其次合 理规划预算也是需要考虑 的重点,通常保险投入占 收入的10%-15%更为 合旋。 "脆皮打工人"关注健康保障 熬夜加班、外卖续命的单身年轻人, 从 ...

N-able, Inc. (NYSE:NABL) Q4 2024 Earnings Conference Call March 3, 2025 8:30 AM ET Company Participants Griffin Gyr - Investor Relations Manager John Pagliuca - President & Chief Executive Officer Tim O'Brien - Executive Vice President, Chief Financial Officer & Principal Conference Call Participants Mike Cikos - Needham Brian Essex - JPMorgan Matt Hedberg - RBC Keith Bachman - BMO Joe Vandrick - Scotiabank Operator Hello, and welcome everyone to the N-able Fourth Quarter 2024 Earnings Call. My name is Beck ...